Who Paid My Doc
Capvaxive
Biological Vaccine
NDC 0006-4347-01
General payments
$1,734,941
Research payments
$9,203,126
Through program year 2025, $1,734,941 in general payments and $9,203,126 in research payments were reported against Capvaxive (Vaccine).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $1,089,471 | 29,512 |
| 2025 | Research | $3,694,788 | 91 |
| 2024 | General | $639,461 | 23,932 |
| 2024 | Research | $5,508,339 | 271 |
| 2023 | General | $703 | 21 |
| 2022 | General | $5,306 | 159 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 137 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 54 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
53,624 general · 362 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.